Precision Blood Transfusion-HemoSure™
Serology has long been served as the gold standard for determining ABO, Rh, and "extended" Human Erythrocyte Antigen (HEA) profiles on red blood cells (RBCs). Commercial antibody reagents are available for ABO, Rh (D, C, c, E, e), and other common HEA specificities; however, reagents remain unavailable for numerous clinically significant antigens. In transfusion medicine, DNA-based genotyping has emerged as an alternative to serology for HEA profiling, facilitating precise donor-recipient matching.
DNA arrays only target a limited panel of single nucleotide polymorphisms (SNPs), precluding comprehensive single-assay analysis of all target HEAs. While NGS (whole genomes, exome, or targeted blood group locus) enables detection of all relevant RBC and platelet antigens, short-read sequencing is constrained by limitations in identifying structural variants, sequencing repetitive regions, phasing distant variants, and differentiating highly homologous genomic regions. Long-read sequencing technologies, however, hold promise for improving the characterization of these challenging genes.
Flexible multi-scenario adaptation solution
Powered by PacBio HiFi sequencing, we have developed the innovative HemoSure™ assay. Equipped with a suite of specialized genotyping panels, it enables precision-driven clinical transfusion practices.
Workflow
Testing Population
Recently received transfusions
Frequently received transfusions (eg, thalassemia)
Positive results on direct antiglobulin testing
Autoimmune hemolytic anemia
Warm antibody of unknown specificity
Antibody to high-frequency antigen
Multiple antibodies
Genotyping of fetus using maternal blood
微信二维码